Effects of Initiating Raltegravir-Based Versus Efavirenz-Based Antiretroviral Regimens During Pregnancy on Weight Changes and Perinatal Outcomes: NICHD P1081

Universidade de São Paulo. Escola de Medicina de Ribeirão Preto. Departamento de Ginecologia e Obstetrícia. Ribeirão Preto, SP, Brasil.
Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Universidade de São Paulo. Escola de Medicina de Ribeirão Preto. Departamento de Ginecologia e Obstetrícia. Ribeirão Preto, SP, Brasil.
Department of Obstetrics and Gynecology, University of Southern California School of Medicine. Los Angeles, CA, USA.
Perinatal HIV Research Unit, University of the Witwatersrand. Johannesburg, South Africa.
Universidade Federal do Rio de Janeiro. Departamento de Doenças Infecciosas. Rio de Janeiro, RJ, Brasil.
University of California. Department of Pediatrics. Los Angeles, CA, USA.
Department of Epidemiology and Applied Biostatistics. Kilimanjaro Christian Medical University College. Moshi, Tanzania.
Hospital Geral de Nova Iguaçu. Departamento de Doenças Infecciosas. Nova Iguaçu, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, Brasil.
Universidade Federal de Minas Gerais. Departamento de Ginecologia e Obstetrícia. Belo Horizonte. MG, Brasil.
Hospital Federal dos Servidores do Estado. Departamento de Doenças Infecciosas. Rio de Janeiro, RJ, Brasil.
Infectious Diseases Department, Hospital Federal dos Servidores do Estado, Rio de Janeiro, Brasil / University of California, Los Angeles, CA, USA.
Maternal and Pediatric Infectious Disease Branch at the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Rockville, MD, USA.
Department of Pediatrics, Boston University School of Medicine, Boston, MA, USA.
Hospital Federal dos Servidores do Estado. Departamento de Doenças Infecciosas. Rio de Janeiro, RJ, Brasil.

Resumo em Inglês

Background: Integrase inhibitors have been associated with excess gestational weight gain that may lead to adverse pregnancy outcomes (APOs). This post hoc analysis of NICHD P1081 compared antepartum changes in weight and body mass index (BMI) in pregnant women initiating raltegravir- or efavirenz-based combined antiretroviral therapy (cART) and examined associations between rates of weight gain and APOs. Setting: NICHD P1081 enrolled antiretroviral-naive pregnant women living with HIV in the second and third trimester in Brazil, Tanzania, South Africa, Thailand, Argentina, and the United States. Methods: Two hundred eighty-one women enrolled between 20 and 31 gestational weeks were randomized to raltegravir- or efavirenz-based cART and followed for $4 weeks. A low rate of weight gain was defined as ,0.18 kg/wk and high as .0.59 kg/wk. We compared weight gain and BMI increase between treatment arms using Kruskal–Wallis tests. Logistic regression was used to investigate the association between weight gain and APOs. Results: Raltegravir-based cART was associated with significantly higher antepartum weight gain (median 0.36 kg/wk versus 0.29 kg/ wk, P = 0.01) and BMI increase (median 0.14 kg/m2/wk versus 0.11 kg/m2/wk, P = 0.01) compared with efavirenz-based treatment.

Palavras-chave

Raltegravir
Efavirenz
Ganho de peso
Índice de massa corporal
Gravidez
Resultados da gravidez

Palavras-chave em inglês

Raltegravir
Efavirenz
Weight gain
Body mass index
Pregnancy
Pregnancy outcomes

Editor

Wolters Kluwer Health, Inc.

Referência

COUTINHO, Conrado Milani et al. Effects of Initiating Raltegravir-Based Versus Efavirenz-Based Antiretroviral Regimens During Pregnancy on Weight Changes and Perinatal Outcomes: NICHD P1081. J Acquir Immune Defic Syndr., v. 91, n. 4, p. 1 - 7, Dec. 2022.

ISSN

1077-9450

Use este identificador para citar ou linkar para este item: https://www.arca.fiocruz.br/handle/icict/57286

Tipo de documento

Direito Autoral

Acesso restrito

Coleções

Compartilhar

Estatísticas

Metadata

Autor(es)

Afiliação